THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [3.38] ID: TIP-MED-000038

Indapamide (Immediate & Sustained Release)

Active Ingredient / Scientific Identity: Indapamide • Class: Thiazide-Like Sulfonamide Diuretic & Vasodilator (Schedule H)

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Indapamide (Immediate & Sustained Release) ([3.38] | ID: TIP-MED-000038) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/3-38-indapamide-immediate-sustained-release/
Generic / Entity NameIndapamide (Immediate & Sustained Release) ([3.38])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassThiazide-Like Sulfonamide Diuretic & Vasodilator (Schedule H)
Available Dosage FormsSustained-Release (SR) Tablets: 1.5 mg; Immediate-Release (IR) Tablets: 2.5 mg; FDCs with Perindopril or Amlod
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Ineffective and contraindicated when eGFR <30 mL/min (switch to Loop diuretic). Hepatic: Contraindicated in severe hep
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Indapamide (Immediate & Sustained Release) (TIP-MED-000038, Reference Code [3.38]) is classified under Cardiovascular & Antithrombotic Medicines (Ch 03) as a Thiazide-Like Sulfonamide Diuretic & Vasodilator (Schedule H). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 03 [3.38], p. 39): Lorvas / Lorvas SR (Servier/Serdia), Natrilix SR (Servier), Indicontin Continus (Modi Mundipharma) — Strengths & Dosage Forms: Sustained-Release (SR) Tablets: 1.5 mg; Immediate-Release (IR) Tablets: 2.5 mg; FDCs with Perindopril or Amlodipine/Telmisartan
Representative Indian Market Examples (Edition 2.7 Ch 03 [3.38], p. 39): Lorvas / Lorvas SR (Servier/Serdia), Natrilix SR (Servier), Indicontin Continus (Modi Mundipharma) — Strengths & Dosage Forms: Sustained-Release (SR) Tablets: 1.5 mg; Immediate-Release (IR) Tablets: 2.5 mg; FDCs with Perindopril or Amlodipine/Telmisartan
Dosage Forms & Available Strengths:
Sustained-Release (SR) Tablets: 1.5 mg; Immediate-Release (IR) Tablets: 2.5 mg; FDCs with Perindopril or Amlodipine/Telmisartan
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Thiazide-Like Sulfonamide Diuretic & Vasodilator (Schedule H) acting on target receptor/enzyme pathways in Cardiovascular & Antithrombotic Medicines (Ch 03): clinical efficacy is mediated via Thiazide-Like Sulfonamide Diuretic & Vasodilator (Schedule H) for Essential hypertension (especially isolated systolic hypertension in the elderly, HYVET trial; and post-stroke BP reduction with Perindopril, PROGRESS trial).

4. Therapeutic Indications & Evidence-Supported Uses

  • Essential hypertension (especially isolated systolic hypertension in the elderly, HYVET trial
  • and post-stroke BP reduction with Perindopril, PROGRESS trial)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: 1.5 mg SR PO OD (preferred) or 2.5 mg IR PO OD in the morning (higher doses do not add BP reduction and only increase hypokalaemia)

Administration & Meal Timing: Take in the morning with water (swallow 1.5 mg SR tablet whole without crushing) | Morning (7:00–9:00 AM — prevents nocturnal diuresis)

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Ineffective and contraindicated when eGFR <30 mL/min (switch to Loop diuretic). Hepatic: Contraindicated in severe hepatic impairment (precipitates hepatic coma)
Elimination & Renal Adjustment:
Renal: Ineffective and contraindicated when eGFR <30 mL/min (switch to Loop diuretic). Hepatic: Contraindicated in severe hepatic impairment (precipitates hepatic coma)
Hepatic Impairment Considerations:
Renal: Ineffective and contraindicated when eGFR <30 mL/min (switch to Loop diuretic). Hepatic: Contraindicated in severe hepatic impairment (precipitates hepatic coma)

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindicated in anuria, severe renal failure (eGFR <30 mL/min), hepatic encephalopathy, severe hypokalaemia/hyponatraemia, and sulfonamide hypersensitivity

Key Clinical Precautions: Renal: Ineffective and contraindicated when eGFR <30 mL/min (switch to Loop diuretic). Hepatic: Contraindicated in severe hepatic impairment (precipitates hepatic coma)

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Hypokalaemia, hyponatraemia, mild hyperuricaemia, dizziness, postural hypotension (more metabolically neutral on lipids/glucose than HCTZ)
  • Severe dilutional hyponatraemia (Na+ <125 mEq/L -> confusion/seizures in elderly women), hypokalaemia-induced QTc prolongation/Torsades, acute gout flare
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Reduces renal Lithium clearance (Lithium toxicity!); hypokalaemia potentiates Digoxin toxicity and QTc-prolonging drugs (Ondansetron, Moxifloxacin, Amiodarone); NSAIDs blunt antihypertensive efficacy

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Take every morning; report muscle cramps, extreme weakness, or confusion/drowsiness (signs of low potassium or sodium); temporary hold during acute dehydration
  • Meal & Clock Timing Instruction: Take in the morning with water (swallow 1.5 mg SR tablet whole without crushing) (Morning (7:00–9:00 AM — prevents nocturnal diuresis))
  • Missed Dose Protocol: Take if remembered before 2:00 PM; if later in the day, skip to avoid nighttime urination
  • Geriatric Dispensing Pearl: Proven stroke and mortality reduction in octogenarians (HYVET trial), but monitor serum Na+ closely in frail elderly women (STOPP/START v3)

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Sustained-Release (SR) Tablets: 1.5 mg; Immediate-Release (IR) Tablets: 2.5 mg; FDCs with Perindopril or Amlodipine/Telmisartan

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 03 [3.38] (p. 39)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/3-38-indapamide-immediate-sustained-release/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.